Hypermarcas (OTCMKTS:HYPMY) Releases Earnings Results

Hypermarcas (OTCMKTS:HYPMY) posted its quarterly earnings results on Wednesday. The company reported $0.13 earnings per share for the quarter, Zacks reports. The firm had revenue of $408.83 million for the quarter. Hypermarcas had a return on equity of 6.99% and a net margin of 12.03%.

Hypermarcas Price Performance

Shares of OTCMKTS HYPMY traded up $0.02 on Friday, hitting $4.80. The company’s stock had a trading volume of 915 shares, compared to its average volume of 56,042. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.26 and a quick ratio of 0.80. The stock has a 50 day moving average of $4.31 and a 200-day moving average of $4.42. Hypermarcas has a 12-month low of $2.64 and a 12-month high of $5.12. The company has a market capitalization of $3.04 billion, a price-to-earnings ratio of 20.87 and a beta of 0.82.

Wall Street Analyst Weigh In

Separately, Scotiabank upgraded shares of Hypermarcas to a “strong-buy” rating in a research report on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Strong Buy”.

Hypermarcas Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.